Edition:
United States

ANI Pharmaceuticals Inc (ANIP.OQ)

ANIP.OQ on NASDAQ Stock Exchange Global Market

67.96USD
3:59pm EST
Change (% chg)

$0.02 (+0.03%)
Prev Close
$67.94
Open
$68.00
Day's High
$68.17
Day's Low
$67.44
Volume
23,370
Avg. Vol
53,176
52-wk High
$74.63
52-wk Low
$42.26

Chart for

About

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.... (more)

Overall

Beta: 2.91
Market Cap(Mil.): $791.03
Shares Outstanding(Mil.): 11.64
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 185.97 15.71
EPS (TTM): -- -- --
ROI: -- -11.84 31.93
ROE: -- -36.93 16.16

BRIEF-ANI Pharmaceuticals Q3 gaap earnings per share $0.40

* ANI Pharmaceuticals reports record third quarter and year-to-date 2017 results and narrows full year guidance

Nov 02 2017

BRIEF-ANI Pharmaceuticals announces launch of Oxycodone Hydrochloride oral solution

* ANI Pharmaceuticals Inc announces approval and launch of Oxycodone Hydrochloride oral solution, 100 mg/5ml

Sep 01 2017

BRIEF-Ani pharmaceuticals reports Q2 adj. earnings of $0.98/shr

* Ani Pharmaceuticals reports record second quarter and year-to-date 2017 results and reaffirms guidance

Aug 03 2017

BRIEF-ANI Pharmaceuticals announced launch of diphenoxylate hcl and atropine sulfate tablets

* Ani Pharmaceuticals Inc - announced launch of diphenoxylate hcl and atropine sulfate tablets, 2.5mg/0.025mg Source text for Eikon: Further company coverage:

Jun 20 2017

Earnings vs. Estimates